Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Tissue factor mediates inflammation.

Arthur J Chu1

  • 1MRC, Shantou University, Shantou, Guangdong 515063, PR China. ajchu91@hotmail.com

Archives of Biochemistry and Biophysics
|July 23, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Quarter-Century Explorations of Bioactive Polyphenols: Diverse Health Benefits.

Frontiers in bioscience (Landmark edition)·2022
Same author

Antagonism by bioactive polyphenols against inflammation: a systematic view.

Inflammation & allergy drug targets·2013
Same author

Tissue factor, blood coagulation, and beyond: an overview.

International journal of inflammation·2011
Same author

Polycations selectively blocking tissue factor-dependent FVII activation: collective in vitro anticoagulation studies.

Inflammation & allergy drug targets·2010
Same author

Blood coagulation as an intrinsic pathway for proinflammation: a mini review.

Inflammation & allergy drug targets·2009
Same author

Role of tissue factor in thrombosis. Coagulation-inflammation-thrombosis circuit.

Frontiers in bioscience : a journal and virtual library·2005
Same journal

Characterizing tumor-associated endothelial cells in clear cell renal cell carcinoma via scRNA-seq and Bulk RNA-seq: construction of a prognostic risk signature.

Archives of biochemistry and biophysics·2026
Same journal

FOSB-Histone deacetylase 6 axis drives hepcidin-mediated ferroptosis in pulmonary ischemia-reperfusion injury.

Archives of biochemistry and biophysics·2026
Same journal

Sevoflurane preconditioning alleviates hypoxia-reoxygenation-induced myocardial injury via regulating the MIR210HG/miR-377-3p/PUM2 axis.

Archives of biochemistry and biophysics·2026
Same journal

Structural and kinetic analysis of human NQO1: Evidence for therapeutic inhibition by racemic warfarin.

Archives of biochemistry and biophysics·2026
Same journal

Mallotus japonicus leaf extract restores TRPM6 magnesium channel expression and suppresses cellular senescence in colonic epithelial cells.

Archives of biochemistry and biophysics·2026
Same journal

Sitosterol-Beta mitigates pulmonary hypertension by targeting SPHK1 in mice.

Archives of biochemistry and biophysics·2026
See all related articles

Tissue factor (TF) drives inflammation through blood coagulation, activating signaling cascades that promote inflammatory responses. Targeting TF, anticoagulation, or protease-activated receptors (PARs) can disrupt this cycle for anti-inflammatory and anti-thrombotic benefits.

Area of Science:

  • Biochemistry
  • Immunology
  • Cardiovascular Biology

Background:

  • Tissue factor (TF) is a key initiator of the extrinsic blood coagulation cascade.
  • TF upregulation is linked to both hypercoagulable and inflammatory states.
  • Coagulant mediators like FVIIa, FXa, and thrombin (FIIa) are proinflammatory.

Purpose of the Study:

  • To elucidate the role of tissue factor in mediating inflammation via blood coagulation.
  • To explore the signaling pathways involved in coagulation-induced inflammation, particularly through protease-activated receptors (PARs).
  • To identify potential therapeutic strategies for interrupting the coagulation-inflammation cycle.

Main Methods:

  • The study reviews the mechanisms by which TF initiates coagulation and triggers inflammatory responses.

Related Experiment Videos

  • It examines the role of serine proteases (FVIIa, FXa, FIIa) and fibrin in promoting inflammation via PARs.
  • It discusses antagonism strategies including TF downregulation, anticoagulation, and PAR blockade.

    • Main Results:

    • TF initiates coagulation cascades involving FVIIa, FXa, and FIIa, leading to fibrin clot production.
    • Proinflammatory mediators generated during coagulation activate PARs, inducing inflammatory responses.
    • Fibrin and its fragments also contribute to inflammation.
    • TF hypercoagulability exacerbates inflammation due to elevated clotting signals.

    Conclusions:

    • TF-mediated coagulation is a significant driver of inflammation.
    • Coagulant mediators and fibrin act as proinflammatory signals.
    • Therapeutic strategies targeting TF, anticoagulation, or PARs can interrupt the coagulation-inflammation cycle.
    • These approaches offer potential for both anti-inflammatory and anti-thrombotic effects, including cardioprotection.